Could new US investment curbs complicate China’s biotech licensing surge?

🇨🇳 Article en anglais

Chinese biotech firms face fresh headwinds in their global expansion as Washington’s proposed outbound investment restrictions threaten to disrupt deal structures, even though drug licensing agreements remain untouched for now, analysts say. The US Treasury Department’s draft rules released last week would “make it much harder for Chinese

Read the original article

Source : South China Morning Post. Le Fil Indépendant cite et lie cet article ; il n'en est ni l'auteur ni l'éditeur.